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Abstract: In the cure of cancer, a major cause of todays
mortality, chemotherapy is the most common treatment,
though serious frequent challenges are encountered by current
anticancer drugs. We discovered that few-layer graphene
(FLG) dispersions have a specific killer action on monocytes,
showing neither toxic nor activation effects on other immune
cells. We confirmed the therapeutic application of graphene on
an aggressive type of cancer that is myelomonocytic leukemia,
where the monocytes are in their malignant form. We
demonstrated that graphene has the unique ability to target
and boost specifically the necrosis of monocytic cancer cells.
Moreover, the comparison between FLG and a common
chemotherapeutic drug, etoposide, confirmed the higher spe-
cificity and toxicity of FLG. Since current chemotherapy
treatments of leukemia still cause serious problems, these
findings open the way to new and safer therapeutic approaches.
The scientific and medical battle against cancer remains one
of the biggest challenges of our times. Cancer is still one of the
major causes of mortality.[1] The blood-related cancers, such
as leukemia in its multiple variants, are among those ones
with the highest incidence of mortality.[2] Acute myeloid
leukemia (AML) and chronic myelomonocytic leukemia
(CMML) represent two different subtypes of the so called
myeloid neoplasms.[3] This type of cancer is usually dominated
by the rapid growth of abnormal immature white blood cell
precursors that accumulate in bone marrow and peripheral
blood interfering with the normal hematopoietic function.[4,5]
Both AML and CMML are characterized by circulating
monocytic neoplastic cells. The conventional treatment of
these disorders is usually based on different chemotherapeu-
tic regimens, which are often characterized by disappointing
remission rates especially in elderly patients. Traditional
therapies to counteract cancer in general, and also myelomo-
nocytic leukemia, are limited by multiple problems, including
nonspecific systemic distribution of antitumor agents, inad-
equate drug concentrations reaching the tumor site, intoler-
able cytotoxicity, limited ability to monitor the therapeutic
responses, and development of multiple drug resistance.[6]
In this scenario, nanotechnology could be the hoped
medical revolution allowing to treat cancer effectively,
reducing undesired side effects.[7] The development of new
nanomaterials endowed of unique properties could represent
a strong enhancement in the cure of cancer. Graphene is one
of the nanomaterials that has raised tremendous interest in
the scientific community and the society.[8] Graphene is being
explored for many potential applications due to its excep-
tional physicochemical characteristics.[9] Very recently, differ-
ent types of graphene have been investigated in a growing
number of medical applications, including drug delivery,
diagnosis, tissue engineering and gene transfection.[10]
In this work, we studied FLG dispersions[11] and discov-
ered a highly specific toxicity on primary human monocytes.
Based on this interesting result, we evaluated the killing
activity of graphene in monocytic neoplastic cells from
a cohort of AML and CMML patients.
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2The majority of the biomedical studies using graphene-
based nanomaterials have focused on graphene oxide, while
there are only a limited number of biological studies on
graphene.[12] The reason for this is the difficulty to disperse
graphene directly in water or in culture media. In this context,
we have prepared few-layer graphene by exfoliation of
graphite through interaction with melamine using a ball-
milling process, under solvent-free conditions.[11] This meth-
odology allows to produce three–four layer graphene dis-
persions in water (0.1 mgmL1). Moreover, water can be
easily replaced by filtration or lyophilization with cell culture
medium to form stable graphene dispersions.[13] Figure 1
shows the relevant characterization data of the FLGmaterial.
Thermogravimetric analysis (TGA) was used to quantify the
presence of functional groups in FLG (Figure 1A). The low
weight loss observed in FLG (7%) confirms the low quantity
of oxygen groups generated during the exfoliation process,
which was also corroborated by elemental analysis (see the
Experimental Section in the Supporting Information). Fur-
ther proof of the non-oxidative milling process was confirmed
by Raman spectroscopy (Figure 1B and the Supporting
Information). Graphene exhibits G and 2D modes around
1573 and 2700 cm1, respectively. The D/G band intensity
ratio, used to quantify the defects, was calculated at different
topographies, giving a significantly low value (0.2). A
representative TEM image of FLG dispersions in cell culture
medium is shown in Figure 1C, evidencing the typical
wrinkled aspect of the graphene flakes. Statistical analysis
of TEM images afforded amajor population with a lateral size
about 500–750 nm, with a small fraction above 2000 nm
(Figure 1D). Additional XPS data are shown in Figure S1 in
the Supporting Information.
FLG stable in cell culture media resulted immediately an
interesting material to study its impact on primary human
immune cells. The use of these cells is at the forefront in the
study of the effects of new materials in a biomedical or
toxicological context.[7c,14] For this purpose, we analyzed the
impact of FLG on peripheral blood mononuclear cell
(PBMC) populations looking at T, B, NK, dendritic cells,
and monocytes. The cells were treated with different doses of
FLG from 0.5 mgmL1 to 75 mgmL1 for 24 h (Figure S2),
which we consider the optimal time for graphene cellular
internalization, and were analyzed by flow cytometry.[14b,15]
Very interestingly, we found a specific cytotoxic activity of
FLG on monocytes (CD14+ cells), while the percentage of
events reported for T, B, NK, and dendritic cells remained
unchanged. This effect is appreciable also in the dot plots,
where the positive events for CD14+ completely disappeared
(Figure 2), and it was not due to the presence of residual
melamine (Figure S3). The other immune cell populations
remained unaffected in terms of cell viability (Figure S4). The
Figure 1. Characterization of FLG. A) Thermogravimetric analysis.
B) Normalized Raman spectrum. C) TEM image of FLG in cell culture
medium and D) lateral dimension distribution.
Figure 2. Impact of FLG on different immune cell populations. A) Rel-
ative percentage of the different immune cells either incubated for
24 h with 50 mgmL1 FLG or left untreated. Statistical significance
compared to untreated cells (Student’s T-test) is indicated by
**=p<0.01. B) Relative morphological dot plots out of at least three
experiments of total PBMCs treated with FLG or left untreated. The
gate on monocytes was done looking at the CD14 positive events (red
dots). The other immune populations are left in green.
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3highly specific effect of FLG was also confirmed by evidenc-
ing its non-cytotoxic impact on other types of cells (Fig-
ure S5).
As we could not record any direct activation of monocytes
(i.e. no significant increase of CD86 expression, Figure S6),
we decided to investigate whether an indirect activation of
monocytes via the activation of T cells was occurring. Indeed,
FLG-mediated activation of T cells could induce a strong
stimulation of monocytes triggering their death.[16] We
analyzed the expression of specific lymphocyte activation
markers, namely CD25 and CD69. Their expression in FLG-
exposed samples was comparable to the untreated negative
controls (Figure S7). These data exclude any T cell activation
mediated by FLG. The absence of activation of the T cells
suggested a direct action of FLG on monocytes. The
hypothesis of a selective activity of the FLG towards
monocytes is consistent with the transmission electron
microscopy (TEM) analysis on total PBMCs (Figure S8).
The fact that only monocytes are able to internalize FLG
could explain our results on cellular activation and cytokine
production. Other reports showed an effect of graphene, and
in particular of GO, on macrophages or DCs.[17] However,
none of them reported such strong specific killing on
monocyte compared to other immune cell populations. In
fact we evidenced that treatments of PBMCs with a commer-
cial graphene oxide do not affect the monocyte population
(Figure S9).[18]
We then investigated the cell death on monocytes isolated
from PBMCs. Monocytes were treated with FLG at
50 mgmL1 and at different time points (1, 4, 12, and 24 h)
to analyze the induced specific death processes (Fig-
ure S10A). The morphological dot plots (Figure S10B)
show the progressive reduction of monocytes (CD14+ cells).
Even at early time points (1 and 4 h) of incubation a signifi-
cant induction of dead cells was observed (Figure S10C). The
necrotic cells increased also significantly from 6.2% in the
control sample to 29% after 1 h and 36.5% after 4 h
(Figure S10A). Mortality of monocytes reached 71.3% after
24 h of incubation with FLG (P-value< 0.01). We also
observed the absence of a significant number of apoptotic
cells in all FLG treated samples (Figure S10A) suggesting
that graphene directly triggers necrosis on monocytes.
To investigate the mechanisms of FLG mediated cell
death we first performed a whole-genome expression, looking
at more than 41,000 transcripts on isolated monocytes from
healthy patients. Venn diagram in Figure S11A shows the
number of genes that passed the cutoff at the different time
points. As expected the number of genes modulated by FLG
increased from 773 after 30 minutes to 836 and 966 after 90
and 270 minutes, respectively. The genes up-regulated by
FLG were mainly chemokines (i.e. CCL1, CCL2, CCL8,
CCL19, CLCL4L2, CXCL1 and CXCL3) and cytokines (i.e.
IL-23a, IL-6, IL-1a, TNF, CSF2 and CSF3) (Table S1). They
all account for the activation process played by FLG on
monocytes that increased proportionally with incubation
time. To understand the biological function of FLG we then
performed a pathway analysis. Figure S11B displays the 10
most significantly modulated pathways corresponding to IL-
10, IL-6 and TREM1 signaling. All these pathways confirmed
again the activating action of FLG on monocytes. IL-10
signaling pathway is in general induced by the activation of
toll-like receptors (TLR) 2 and 4 with the regulation of the
inflammation through the inhibition of pro-inflammatory
cytokines TNFa and IL-6.[19] It was previously evidenced how
the internalization of graphene could be mediated by TLR2
and TLR4.[18a] The toxicity of our FLG is likely induced by the
activation of both TLR signaling via TNFa production.[19,20]
To investigate whether TLR2/TLR4 receptors were involved
in the selective cytotoxic effect of FLG on monocytes, we
analyzed ex vivo the monocytes treated with and without
TLR2/TLR4 blocking antibodies. The experiments revealed
that TLR4 seems not or only partially involved in the
mechanism inducing selective cell death of monocyte by
FLG (Figure S12A). Instead, the inhibition of TLR2 blocked
the expression of CD25 in treated monocytes (Figure S12B).
Moreover, the inhibition of TLR2 was able to restore the
number of monocytes compared to the controls. Together
with the gene expression analysis, these results suggest that
the FLG toxicity on monocytes is mediated by the interaction
of FLG with TLR2 and the subsequent expression of TNFa
and TNFR family (see also the Supporting Information).[21]
The high selective capacity of our FLG to kill human
monocytes is promising for the treatment of myelomonocytic
leukemia, which presents high percentages of circulating
monocytic neoplastic cells. Therefore, we analyzed the effect
of FLG as a new chemotherapeutic tool in myeloid malig-
nancies. In particular, we evaluated the monocytoid CD14+
cell viability in PBMCs obtained from a cohort of seven
patients (6 male and 1 female) with a median age of 70, newly
diagnosed with AML or CMML, before starting the ther-
apeutic treatment (Figure 3). The presence of FLG accumu-
lated into the monoblasts (Figure S13A) was observed into
the peripheral blood smear of AML (Figure S13B) and
CMML (Figure S13C) patients. PBMCs of the patients were
then treated with increasing doses of FLG to assess the
capacity of graphene to specifically kill the neoplastic
monocytes. In the untreated samples of all patients
(Figure 3), two peaks of cells are well visible: the first on
the left comprises all cells negative to the CD14 marker
corresponding to non-neoplastic cells (i.e. T cells, B cells, NK
and dendritic cells), while the peak on the right identifies
CD14+ monocytoid cancer cells. After the treatment with
FLG, the cancer cell population was strongly reduced in all
AML and CMML patients in an FLG concentration depen-
dent manner with no effect on the other immune cells
(Figure 3). We would like to point out that in the 6 patients,
the number of cancer cells was strongly reduced even at low
concentrations (0.5 and 5 mgmL1) with two fold, and three
fold average decrease, respectively. Regarding the ablation
obtained at 25 and 50 mgmL1, the percentage of cells was
extremely reduced from an average of 24% to an average of
2.2% and 1.6%, respectively (Figure 3 and Figure S14). In
particular, patient 4 was characterized by a critical condition
with an extremely high number of monocytoid cancer cells
comparable to all other immune cells. The treatment with
FLG even at the lower concentrations has shown 40% and
83% reduction of the neoplastic cell number, reaching the
total ablation at 25 mgmL1 (Figure 3, Pt.4). The analysis of
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4the cytokine secretion in CMML patients after the treatment
with FLG did not evidence any induction of inflammatory
processes in other immune cells. Thus, only monocyte-
associated cytokines were found overexpressed under FLG
treatment (Figure S15).
Furthermore, we compared the specific effect of FLGwith
etoposide, a common chemotherapeutic agent clinically used
in the treatment of both AML and CMML. Etoposide was
specifically selected because of its ability to selectively induce
monocytopenia, the deficiency of monocytes mandatory to
prevent tumor expansion.[22] We tested concentration of
etoposide between 50 and 200 mm, normally used to treat
AML and CMML.[23] The comparison of the effect of FLG at
50 mgmL1 with the different etoposide doses in PBMCs
isolated from AML patients underlines the safety use of FLG
with no toxic effect on the other immune cell populations
(Figure 4A). As expected, etoposide induced a significant T,
B and NK cell toxicity at all concentrations (Figure 4A). In B
cells, we found a 49.6% of dead cells at the lowest concen-
tration and a 68.3% at the highest. We further confirmed the
strong specific effect of FLG on neoplastic CD14+ cells
compared to etoposide (Figure 4B). These findings open the
way to a possible application of FLG as a specifically targeted
tool against neoplastic cells in AML and CMML. This new
therapeutic strategy based on graphene might be extremely
advantageous over the traditional treatments using conven-
tional chemotherapeutic agents such as etoposide, cytarabine,
anthracyclines or hydroxyurea,[4,5] that
are non specific and impair all immune
cell subpopulations, causing possible
infections and death. Moreover, some
of these chemotherapies act by activat-
ing the apoptosis pathway in tumor
cells. Paradoxically, the fact that anti-
cancer agents are effective primarily
because they activate apoptosis raises
the concern that tumors intrinsically
resistant to chemotherapy are unable to
activate the apoptotic machinery and
may be resistant to any chemothera-
peutic drug.[24] The necrosis-mediated
action of FLG could avoid the resist-
ance of tumor cells.
Finally, given the complexity of the
toxicology and pharmacokinetic issues
with graphene-based materials, we
characterized the systemic body reac-
tion to FLG in vivo. All injected mice
behaved normally and did not show
signs of adverse reactions (see Fig-
ure S16).
In summary, in this work, we found
a specific toxicity of FLG on primary
human monocytes. In particular, we
demonstrated a unique ability of gra-
phene to target and successfully boost
the necrosis of monocytoid cancer cells
for acute myeloid leukemia and chronic
myelomonocytic leukemia patients.
Moreover, the comparison between FLG and a common
chemotherapeutic drug confirmed the specificity and higher
toxicity of FLG on cancer cells, evidencing the absence of
toxicity on other immune cell populations. Considering the
FLG specific ability to target and kill cancer cells of an
aggressive form of malignancy, extremely promising poten-
tials as a new cancer tool can be envisaged for graphene.
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